A review of the establishment of patient-derived prostate cancer xenograft( PDX) model and screening of therapeutic drugs
10.3969/j.issn.1005-4847.2018.03.018
- VernacularTitle:前列腺癌人源性异种移植模型的建立及治疗药物的筛选
- Author:
Xue CHEN
1
;
Changhong SHI
Author Information
1. 成都医学院基础医学院
- Keywords:
prostate cancer;
patient-derived xenograft ( PDX ) model;
androgens;
stromal niche;
therapeutic drugs
- From:
Acta Laboratorium Animalis Scientia Sinica
2018;26(3):386-391
- CountryChina
- Language:Chinese
-
Abstract:
The high-fidelity prostate tumor patient-derived xenograft ( PDX) model is the basis for studies of biology and pharmacotherapy of prostate cancer. However, the development and application of prostate tumor has been hampered by a low success rate of transplanted primary tumors in mice as most prostate cancers are highly relevant to hormones. The high-fidelity PDX model of prostate cancer better maintains the histopathology and molecular heterogeneity of the original tumor. Here, we review the improved method of establishing PDX model of prostate cancer, including the testosterone supplementation, the quality of the original tumor tissue as well as the stromal niche, and the application of commonly used therapeutic drugs, and to provide a theoretical basis for clinical studies of prostate tumor. These attempts are very important for development of new agents and research on mechanisms of prostate cancer. It will further promote the individualized treatment of prostate cancer.
